Microbial conversion of rapamycin

Enzyme and Microbial Technology

Volumn 21, Issue 6, 1997, Pages 405-412

  Kuhnt, Michaela ^a   Bitsch, Francis ^a   Ponelle, Monique ^a   Fehr, Theo ^a   Sanglier, Jean Jacques ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

16 o demethylsecorapamycin B; 24 hydroxyrapamycin; Biotransformation; FKBP; Mouse mixed lymphocyte reaction; Rapamycin; Secorapamycin A, B and C

Indexed keywords

BACTERIA; BIOCONVERSION; BIOTECHNOLOGY; DERIVATIVES; FERMENTATION; FUNGI; REACTION KINETICS;

BIOTRANSFORMATION; RAPAMYCIN;

ANTIBIOTICS;

FK 506 BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ARTICLE; BACILLUS SUBTILIS; BACTERIUM; BINDING AFFINITY; BIOTRANSFORMATION; DRUG PROTEIN BINDING; DRUG SCREENING; FUNGUS; NONHUMAN; STREPTOMYCES;

EID: 0031281716     PISSN: 01410229     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0141-0229(97)00013-6     Document Type: Article

References (13)

1. Vezinna, C., Kudelski, A., and Sehgal, S. N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiotics 1975, 28, 721-726
2. Sehgal. S. N., Baker, H., and Vezinna, C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation, and characterization. J. Antibiotics 1975, 28, 727-732
3. Chen, H., Luo, H., Daloze, P., Xu, D., and Wu, J. Rapamycin-induced long-term allograft survival depends on persistence of alloantigen. J. Immunol. 1994, 152, 3107-3118
4. Bierer, B. E., Matilla, P. S., Staendert, R. F., Herzenberg, L. A., Burakoff, S. J., Crabtree, G., and Schreiber, S. L. Two distinct transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc. Natl. Acad. Sci. USA 1990, 87, 9231-9235
5. Johnson, R. A. Oxygenations with microorganisms. In: Oxidation in Organic Synthesis. Part C. (Trahanovsky, W. S., Ed.). Academic Press, New York, 1978, 131-210
6. Meo, T. The MLR test in the mouse. In: Immunological Methods (Levkovits, I. and Pernis, B., Eds.). Academic Press, New York, 1979, 227-239
7. Fehr, T., Sanglier, J. J., Schuler, W., Gschwind, L., Ponelle, M., Schilling, W., and Wioland, C. Antascomicins A, B, C, D, and E. Novel FKBP12 binding compounds from a Micromonospora strain. J. Antibiotics 1996, 49, 230-233
8. Nishida, H., Sakakibara, T., Aoki, F., Saito, T., Ichikawa, K., Inagaki, T., Kojima, Y., Yamaguchi, Y., Huang, H. L., Guadliana, M. A., Kaneko, T., and Kojima, N. Generation of novel rapamycin structures by microbial manipulations. J. Antibiotics 1995, 48, 657-666
9. Christians, U., Sattler, M., Schiebel, H. M., Kruse, C., Radeke, H. H., Linck, A., and Sewing, K. F. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab. Dispos. 1992, 20, 186-191
10. Box, S. J., Shelley, P. R., Tyler, J. W., Verall, M. S., and Warr, S. R. 27-o-demethylrapamycin, an immunosuppressant compound produced by a new strain of Streptomyces hygroscopicus. J. Antibiotics 1995, 48, 1347-1349
11. Chen, S. S. T., Petuch, B. R., Arison, B. H., Dumont, F., White, R. F., Mathre, D. J., Wu, J. T., and Reamer, R. A. New process for biophosphorylating organic compounds. Parent WO 92/06992, April 1992
12. Wang, P., Chan, K. W., Sciksnis, R. A., Scatina, J., and Sisenwine, S. F. High performance liquid Chromatographic isolation, spectroscopic characterization, and immunosuppressive activities of two rapamycin degradation products. J. Liq. Chromat. 1994, 17, 3383-3392
13. Sabatini, D. M., Erdjument-Bromage, H., Liu, M., Tempst, P., and Snyder, S. H. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994, 35, 35-43